Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient's own cells. The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company's product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:TNGN
CUSIPN/A
Phone+1-336-7225855
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets-618.10%
Miscellaneous
EmployeesN/A
Outstanding Shares36,620,000
Market Cap$20,120.00
Tengion (OTCMKTS:TNGN) Frequently Asked Questions
What is Tengion's stock symbol?
Tengion trades on the OTCMKTS under the ticker symbol "TNGN."
Who are Tengion's key executives?
Tengion's management team includes the folowing people:
- David I. Scheer, Independent Chairman of the Board (Age 63)
- Carl-Johan Dalsgaard M.D., Independent Director (Age 56)
- Diane K. Jorkasky M.D., Independent Director (Age 61)
- Richard E. Kuntz M.D., Independent Director (Age 58)
- Lorin Jeffry Randall, Independent Director
Has Tengion been receiving favorable news coverage?
Media headlines about TNGN stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tengion earned a media and rumor sentiment score of 0.03 on Accern's scale. They also assigned news stories about the company an impact score of 49.91 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Tengion.
How do I buy shares of Tengion?
Shares of TNGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tengion's stock price today?
One share of TNGN stock can currently be purchased for approximately $0.0005.
How big of a company is Tengion?
Tengion has a market capitalization of $20,120.00.
How can I contact Tengion?
Tengion's mailing address is 3929 Westpoint Blvd Ste G, WINSTON SALEM, NC 27103-6761, United States. The company can be reached via phone at +1-336-7225855.
MarketBeat Community Rating for Tengion (OTCMKTS TNGN)
MarketBeat's community ratings are surveys of what our community members think about Tengion and other stocks. Vote "Outperform" if you believe TNGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
